Nivolumab and ipilimumab in the treatment of metastatic renal cell carcinoma. Report of two patients

Ferlay, 2013 Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence – SEER 9 Regs Research Data, Nov 2015 Sub (1973–2013) <Katrina/Rita Population Adjustment> – Linked To County Attributes – Total U.S., 1969–2014 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2016, based on the November 2015 submission. Eble, 2004, World Health Organization Classification of Tumours Tarek, 2005, Validation and extension of the memorial sloan kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma, J Clin Oncol, 23, 832, 10.1200/JCO.2005.05.179 Motzer, 2013, Pazopanib versus sunitinib in metastatic renal-cell carcinoma, N Engl J Med, 369, 722, 10.1056/NEJMoa1303989 Motzer, 2015, Nivolumab versus everolimus in advanced renal-cell carcinoma, N Engl J Med, 373, 1803, 10.1056/NEJMoa1510665 Yang, 2007, Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis, J Immunother, 30, 825, 10.1097/CJI.0b013e318156e47e Fyfe, 1995, Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy, J Clin Oncol, 13, 688, 10.1200/JCO.1995.13.3.688 Chen, 2013, Oncology meets immunology: the cancer–immunity cycle, Immunity, 39, 1, 10.1016/j.immuni.2013.07.012